Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia

Eur Urol. 1991:20 Suppl 1:82-6. doi: 10.1159/000471752.

Abstract

Finasteride is a potent competitive 5 alpha-reductase inhibitor, active at a dose as low as 1 mg/day. After a single dose, the effects on 5 alpha-reductase last as long as 7 days. Both hepatic and target tissue 5 alpha-reductase are inhibited. Plasma testosterone and estradiol are unaffected and luteinizing hormone levels do not change. During chronic treatment with finasteride 5 mg/day, the effects on 5 alpha-reductase are maintained. Since the only significant effect of chronic finasteride therapy appears to be 5 alpha-reductase inhibition, and testosterone or estradiol levels are not affected, neither libido nor potency is lost. Testosterone is the active androgen at the muscular level; therefore, muscular catabolism is not expected.

Publication types

  • Clinical Trial

MeSH terms

  • 5-alpha Reductase Inhibitors*
  • Androgens / blood
  • Androstenes / administration & dosage
  • Androstenes / therapeutic use*
  • Azasteroids / administration & dosage
  • Azasteroids / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Estradiol / blood
  • Finasteride
  • Humans
  • Luteinizing Hormone / blood
  • Male
  • Prostatic Hyperplasia / blood
  • Prostatic Hyperplasia / drug therapy*
  • Testosterone / blood

Substances

  • 5-alpha Reductase Inhibitors
  • Androgens
  • Androstenes
  • Azasteroids
  • Testosterone
  • Estradiol
  • Finasteride
  • Luteinizing Hormone